DACLAHEP

Daclahep contains daclatasvir 60 mg tablet (equivalent to daclatasvir dihydrochloride). Daclatasvir is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir for treatment of chronic HCV genotype 3 infection.

The recommended dosage of Daclahep is 60mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. Daclahep may be taken with or without food.